Abstract
Psoriasis is now more recognized as a chronic-lymphocyte mediated inflammatory and proliferous skin disease. In European countries, the prevalence of psoriasis is 1%~3%, so the study of psoriasis is very important. With the study of immune pathogenesis and the progress of genetic engineering technology, it has been gradually developed a wide range of biological agents, And achieved good results in clinical trials or clinical treatment. This paper discusses the typical clinical manifestations, genetic research and treatment of psoriasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have